Decreased neurotrophin TrkB receptor expression reduces lesion size in the apolipoprotein E-null mutant mouse

Circulation

Volumn 112, Issue 23, 2005, Pages 3644-3653

  Kraemer, Rosemary ^a   Baker, Peter James ^a   Kent, K Craig ^a   Ye, Yuanfen ^a   Jun, Ji Han ^a   Tejada, Rafael ^a   Silane, Michael ^c   Upmacis, Rita ^a   Deeb, Ruba ^a   Chen, Yaoxin ^b   Levine, Daniel M ^b   Hempstead, Barbara ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Arteriosclerosis; Neurotrophins; Smooth muscle cells; Trk receptors; Vasculature

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CHOLESTEROL; FATTY ACID; LIPID; NEUROTROPHIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHEMOTAXIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID BLOOD LEVEL; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; ANIMAL; ARTERIOSCLEROSIS; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; MACROPHAGE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SMOOTH MUSCLE FIBER;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHEMOTAXIS; CHOLESTEROL; GENE EXPRESSION REGULATION; MACROPHAGES; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; RECEPTOR, TRKB;

EID: 33644873541     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.587980     Document Type: Article

References (43)

1. 3 Integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77:1129-1135.
2. 3 Integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 1998;97:907-915.
3. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-67.
4. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol. 2002;160:2145-2155.
5. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
6. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773-778.
7. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-429.
8. Boucher P, Gotthardt M, Li W-P, Anderson RGW, Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science. 2003;300:329-332.
9. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, Kita T. Functional blockade of platelet-derived growth factor receptor-β but not of receptor-α prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation. 2001;103:2955-2960.
10. Kozaki K, Kaminski WE, Tang J, Hollenbach S, Lindahl P, Sullivan C, Yu J-C, Abe K, Martin PJ, Ross R, Betsholtz C, Giese NA, Raines EW. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in Apo E null mice. Am J Pathol. 2002;161:1395-1407.
11. Donovan MJ, Miranda RC, Kraemer R, Mccaffrey TA, Tessarollo L, Mahadeo D, Sharif S, Kaplan DR, Tsoulfas P, Parada L, Toran-Allerand D, Hajjar DP, Hempstead BL. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells: regulation of expression in response to injury. Am J Pathol. 1995;147:309-324.
12. Kraemer R, March KL, Hempstead BL. NGF activates similar intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB but elicits different biological responses. Arterioscler Thromb Vasc Biol. 1999;19:1041-1050.
13. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci. 2003;26:299-330.
14. Donovan MJ, Lin M, Wiegn P, Ringsted T, Kraemer R, Hahn R, Wang S, Ibanez C, Rafii S, Hempstead BL. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531-4540.
15. Khan KMF, Nguyen H, Falcone DJ, Kraemer R. NGF activation of Erk-1 and Erk-2 induces MMP-9 expression in vascular smooth muscle cells. J Biol Chem. 2002;277:2353-2359.
16. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
17. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
18. Heissig B, Hattori K, Dias S, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MAS, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit ligand. Cell. 2002;109:625-637.
19. Klein R, Smeyne RJ, Wurst W, Long LK, Auervach BA, Barbacid M. Targeted disruption of the Trk B neurotrophin receptor results in nervous system lesions and neonatal death. Cell. 1993;75:113-122.
20. Labouyrie E, Dubus P, Groppi A, Mahon FX, Ferrer J, Parrens M, Reiffers J, de Mascarel A, Merlio JP. Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol. 1999;154:405-415.
21. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A, Sunagawa K. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerotic and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2003;24:e174-e178.
22. Guo J, Van Eck M, Twisk J, Maeda N, Benson GM, Groot PHE, Van Berkel TJC. Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:447-453.
23. 3CR1 -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003;111:333-340.
24. Gerthoffer WT, Singer CA. Secretory functions of smooth muscle cells: cytokines and growth factors. Mol Intervent. 2002;2:447-456.
25. Falcone D, McCaffrey T, Haimovitz-Friedman A, Vergilio J, Nicholson A. Macrophage and foam cell release of matrix-bound growth factors: role of plasminogen activation. J Biol Chem. 1993;268:11951-11958.
26. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317-1326.
27. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445-465.
28. Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Exp Rev Mol Med. 2001;2001:1-18.
29. Boisvert WA. Modulation of atherogenesis by chemokines. Trend Cardiovasc Med. 2004;14:161-165.
30. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol. 2004;15:145-149.
31. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, Tedgui A. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934.
32. Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C. INF-γ potentiates atherosclerosis in Apo E knock-out mice. J Clin Invest. 1997;99:2752-2761.
33. Whitman SC, Ravisankar P, Daugherty A. INF-γ deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E -/- mice. J Interferon Cytokine Res. 2002;22:661-670.
34. Kim H, Li Q, Hempstead BL, Madri JA. Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. J Biol Chem. 2004;279:33538-33546.
35. Kermani P, Rafii D, Jin DK, Whitlock P, Schaffer W, Chiang A, Vincent L, Friedrich M, Shido K, Hackett NR, Crystal RG, Rafii S, Hempstead BL. Neurotrophins promote revascularization by local recruitment of Trk B+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest. 2005;115:653-663.
36. Isner JM. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation. 1999;99:1653-1655.
37. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003;100:4736-4741.
38. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNF-470 reduced intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99:1726-1732.
39. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovings S. Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:2137-2142.
40. Niwa T, Wada H, Ohashi H, Iwamoto N, Ohta H, Kirii H, Fujii H, Saito K, Seishima M. Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J Atheroscler Thromb. 2004;11:79-87.
41. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH, Wihler C, Kiliatsos VE, Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A. 1999;96:15239-15244.
42. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000;19:1290-1300.
43. Combadiere C, Potteaux S, Gao J-L, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CXCR1/apolipoprotein E double knockout mice. Circulation. 2003;107:1009-1016.